The Health Promotion Agency/Te Hiringa Hauora (HPA) has undertaken some research to provide insight into attitudes, awareness and concern toward ultra-violet (UVR) radiation, primarily for outdoor socialisers in the age group of 18-24 years. The research findings identified that despite outdoor socialisers having a high awareness of identified/known SunSmart behaviours, it does not always translate into using SunSmart behaviours.
According to this recent study, there is an association between improved overall survival and the onset of immune-related adverse events in ipilimumab/nivolumab combination therapy.
The national health service in England has comprehensive databases which were used in this study to track prescribing of checkpoint inhibitors (CPIs) approved for first line use in metastatic melanoma and determine patient outcomes associated with survival and treatment toxicity. This largest real world dataset demonstrated rapid uptake of CPIs and survival outcomes similar to randomized clinical trials (RCTs).
According to this recent study, in patients with stage III/IV melanoma treated with immune checkpoint inhibitors (ICI), receipt of antibiotics within 3 months prior to ICI initiation was associated with decreased overall survival and increased colitis.
This chapter reviews the clinical, molecular, and immunological characteristics of acral, mucosal, and uveal melanoma in the context of systemic therapy in both the advanced disease setting as well as the adjuvant setting. It also contains a review of emerging data on new therapeutic options and the use of systemic therapy in additional clinical settings such as in the neoadjuvant setting.
This paper discusses that there is still an unmet need in melanoma treatment: A significant population of patients did not respond to either BRAF inhibitors or immune checkpoint inhibitors, or would develop drug resistance even when MEK inhibitors were added to the treatment. It also discusses some possible targets for melanoma treatment.
While surgical and medical management still follows adult guidelines, recently there has been a better understanding of specific characteristics of pediatric melanoma. First pediatric clinical studies have been conducted.
Recently, algorithms have been developed that combine information about various phenotypic characteristics to derive an overall summary risk score. Such tools are being tested as decision aids to stratify individuals into potential screening programs according to their future risk of melanoma.
This chapter summarizes the development and use of cytokines as single agents or in combination in the treatment of patients with advanced metastatic melanoma.
This chapter presents the evidence and illustrative cases for radiation therapy in locoregional melanoma.